CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Marc Rubin, M.D. to its Board of Directors. Dr. Rubin brings extensive clinical development, medical, commercial and scientific expertise to Curis, having held executive-level clinical development positions with Bayer Schering Pharma, Schering AG and GlaxoSmithKline.
